# Ledipasvir + Sofosbuvir

## Harvoni 90/400mg

##### 臨採

| TAH Drug Code      | OHARV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of chronic HCV genotype 1 infection in adults.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Dosing             | One tablet once daily with concomitant ribavirin for 12 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | If ledipasvir/sofosbuvir is administered with ribavirin, the contraindications to ribavirin also apply. Hypersensitivity to any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | >10%: Central nervous system: Headache (11% to 29%), fatigue (10% to 18%) Neuromuscular & skeletal: Weakness (18% to 31%) 1% to 10%: Central nervous system: Irritability (8%), insomnia (3% to 6%), dizziness (5%), depression (<5%; including in subjects with preexisting history of psychiatric illness) Gastrointestinal: Nausea (6% to 9%), increased serum lipase (>3 x ULN: ?9%), diarrhea (3% to 7%) Hepatic: Hyperbilirubinemia (>1.5 x ULN: ?3%) Neuromuscular & skeletal: Myalgia (9%), increased creatine phosphokinase (1%) Respiratory: Cough (5%), dyspnea (3%) <1% (Limited to important or life-threatening): Skin rash (with blisters or angioedema-like swelling) |
| Pregnancy          | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

